Synchron Closes $310M Series E to Accelerate Stentrode BCI Toward Commercial Clearance

Funding Round and Capital Deployment

Synchron announced today the close of a $310 million Series E funding round, marking one of the largest single financing events in brain-computer interface history and signaling sustained institutional confidence in the endovascular BCI approach. The round was co-led by ARCH Venture Partners and SoftBank Vision Fund 3, with participation from existing investors including Khosla Ventures, NVIDIA's venture arm, and a consortium of strategic healthcare systems based in the United States and Australia.

The New York- and Melbourne-headquartered company will deploy the capital across three primary initiatives: scaling domestic manufacturing capacity for its Stentrode device, expanding its ongoing COMMAND pivotal trial to 18 additional clinical sites across North America and Europe, and building out the regulatory affairs infrastructure required to support a U.S. Food and Drug Administration De Novo authorization submission targeted for the fourth quarter of 2027.

Stentrode Technology and Clinical Progress

Stentrode is distinguished from competing BCI platforms by its minimally invasive delivery mechanism. The device is implanted via the jugular vein and positioned within the superior sagittal sinus adjacent to the motor cortex, eliminating the need for open-brain surgery. The approach has been central to Synchron's commercial differentiation thesis, particularly as the company targets an ALS and severe paralysis patient population for whom surgical risk profiles are an acute clinical concern.

CEO Tom Oxley stated that the new capital positions Synchron to transition from proof-of-concept to scalable therapy within a defined regulatory timeline. The company reported earlier this year that participants in its U.S. feasibility study have now accumulated more than 1,200 combined device-days, with no serious adverse events attributed to the implant and sustained neural signal quality across the cohort.

Broader BCI Market Landscape

The funding announcement arrives at an inflection point for the broader BCI sector. Neuralink received its FDA Breakthrough Device designation renewal in March, while Precision Neuroscience disclosed interim data from its Layer 7 cortical interface study at the International Neuroethics Society conference last month. Analysts at SVB Securities estimate the addressable market for implantable BCIs targeting motor restoration will exceed $4.2 billion annually by 2032, contingent on at least one device achieving broad commercial reimbursement coverage in the United States.

Synchron's Series E brings its total raised capital to approximately $595 million. The company indicated it expects to announce two new industry partnership agreements before the end of Q3 2026.